SDX 102
Alternative Names: Alanosine; L-alanosine; NSC-153353Latest Information Update: 02 Oct 2021
At a glance
- Originator National Cancer Institute (USA); University of California, San Diego
- Developer Salmedix
- Class Cytostatic antibiotics
- Mechanism of Action Adenylosuccinate synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Brain cancer; Mesothelioma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Pancreatic cancer; Sarcoma